Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma
Open Access
- 13 June 2017
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 96 (1), 1-4
- https://doi.org/10.1159/000464282
Abstract
Background: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. Summary: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors. These treatment options include radiofrequency ablation (RFA), transarterial chemoembolization (TACE), selective internal radiotherapy with yttrium-90 (SIRT), stereotactic body radiation therapy (SBRT), proton beam therapy, molecular targeted therapy, and checkpoint inhibition. In this “to-the-point” article, we review the current standard and summarize the most recent findings in unresectable HCC treatment. Key Points: (1) RFA is currently the preferred treatment for patients with tumor burden restricted to the liver and not eligible for surgical resection; (2) TACE is utilized in patients who are not eligible for RFA because of tumor location and/or number of tumor lesions; (3) SIRT might improve treatment responses achieved by TACE and is feasible in patients with portal vein thrombosis; (4) new radiation therapy treatment modalities such as SBRT and proton beam therapy show promising results for local tumor control; and (5) sorafenib remains the first-line systemic treatment option after several large clinical trials have failed to show superiority of other molecular targeted therapies in HCC patients.Keywords
This publication has 16 references indexed in Scilit:
- Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular CarcinomaJournal of Clinical Oncology, 2016
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2015
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2015
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2015
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2015
- Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort StudyAmerican Journal Of Gastroenterology, 2014
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib TreatmentCancer Discovery, 2014
- Diagnostik und Therapie des hepatozellulären KarzinomsZeitschrift für Gastroenterologie, 2013
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyThe Lancet Oncology, 2012
- Resection of hepatocellular cancer ≤2 cm: Results from two Western centersHepatology, 2012